文献速递主动脉疾病

慢性阻塞性肺疾病与胸主动脉及复杂主动脉腔内修复术后死亡率的关联

Association of Chronic Obstructive Pulmonary Disease and Mortality Following Thoracic and Complex Endovascular Aortic Repair.
PubMed 文献 · Ann Vasc Surg · 2025-01-23

基于血管质量倡议数据库2013至2022年择期TEVAR和CEVAR病例的回顾性分析,按COPD严重程度分层,评估院内死亡、呼吸系统并发症和1年死亡率。结果显示COPD严重程度与呼吸系统并发症及1年死亡率独立相关,应纳入术前决策。

要点

  • COPD严重程度与TEVAR/CEVAR术后呼吸系统并发症风险增加独立相关。
  • COPD严重程度与1年死亡率风险增加独立相关,应纳入术前决策。
  • 院内死亡率随COPD严重程度升高,但多因素校正后未显示独立关联。

核心结论

  • 接受TEVAR和CEVAR的COPD患者院内死亡率、呼吸系统并发症和1年死亡率均升高。
  • COPD严重程度与呼吸系统并发症和1年死亡率增加独立相关,应纳入术前决策。

研究设计与样本

  • 回顾性分析血管质量倡议数据库2013至2022年择期TEVAR和CEVAR病例,纳入近端锚定区≥2的胸主动脉或复杂腹主动脉疾病患者。
  • 排除有症状疾病、破裂以及紧急或急诊手术,共纳入11,336例患者,按COPD严重程度分层。
  • 主要结局为院内死亡率,次要结局包括呼吸系统并发症和1年死亡率,采用多因素logistic回归分析。

主要发现

  • 11,336例患者中,66%无COPD,9%有COPD未用药,20%有COPD用药,6%有COPD家庭补充氧疗。
  • 院内死亡率分别为2.3%、3.7%、3.2%和4.5%(P=0.0004),但多因素分析未显示与死亡率几率增加相关。
  • 呼吸系统并发症发生率分别为4.3%、4.5%、6.4%和7.3%(P<0.0001),COPD用药组OR 1.3,家庭补充氧疗组OR 1.7。
  • 1年生存率分别为91%、87%、86%和80%,各COPD组风险增加(HR 1.4、HR 1.4、HR 1.9)。

临床怎么用

  • 作者认为COPD严重程度应纳入TEVAR和CEVAR的术前决策。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study assessed the association between chronic obstructive pulmonary disease (COPD) severity and postoperative mortality among patients undergoing thoracic endovascular aortic repair (TEVAR) and complex endovascular aortic repair (CEVAR). METHODS: A retrospective review of the Vascular Quality Initiative database identified elective TEVAR and CEVAR cases from 2013 to 2022, with endograft proximal landing zone ≥2 for thoracic or complex abdominal aortic disease. Symptomatic diseases, ruptures, and urgent or emergent surgeries were excluded. Patients were stratified by COPD severity. The primary outcome was in-hospital mortality. Secondary outcomes included respiratory complications and 1-year mortality. Multivariable logistic regression was used for in-hospital mortality, respiratory complications, and 1-year mortality. RESULTS: Among 11,336 patients with TEVAR and CEVAR, 66% did not have COPD, 9% had COPD not on medications, 20% had COPD on medications, and 6% had COPD on home supplemental oxygen. In-hospital mortality was 2.3%, 3.7%, 3.2%, and 4.5% (P = 0.0004) respectively, and was not associated with increased odds of mortality. Respiratory complications occurred in 4.3%, 4.5%, 6.4%, and 7.3% (P < 0.0001) and were associated with increased odds for COPD on medications (OR 1.3) and COPD on home supplemental oxygen (OR 1.7). 1-year survival was 91%, 87%, 86%, and 80% and associated with increased risk for each COPD group (HR 1.4, HR 1.4, HR 1.9). CONCLUSION: Patients with COPD undergoing TEVAR and CEVAR have increased rates of in-hospital mortality, respiratory complications, and 1-year mortality. COPD severity is independently associated with increased respiratory complications and 1-year mortality, which should be factored into preoperative decision-making.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. DiBartolomeo AD, Ding L, Han SM, et al. Association of Chronic Obstructive Pulmonary Disease and Mortality Following Thoracic and Complex Endovascular Aortic Repair. Ann Vasc Surg. 2025. PMID: 39863283. doi:10.1016/j.avsg.2024.12.080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。